OmniAb (OABI) Common Equity (2021 - 2026)
OmniAb (OABI) reported Common Equity of $262.6 million for Q1 2026, down 3.97% year-over-year from $273.5 million in Q1 2025, and down 1.64% on a QoQ basis from $267.0 million in Q4 2025.
OmniAb (OABI) has 6 years of Common Equity data on file, last reported at $262.6 million in Q1 2026.
- Quarterly Common Equity fell 3.97% year-over-year to $262.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $262.6 million (down 3.97% YoY) and the FY2025 annual result came in at $267.0 million, down 7.16% from the prior year.
- Common Equity slipped to $262.6 million in Q1 2026 per OABI's latest filing, from $267.0 million in the prior quarter.
- Across five years, Common Equity topped out at $341.4 million in Q4 2022 and bottomed at $224.9 million in Q1 2022.
- The 5-year median for Common Equity is $287.6 million (2024), against an average of $285.7 million.
- The widest annual swing landed in 2022, when Common Equity jumped 1509933.93%; it then decreased 11.87% in 2024.
- Tracing OABI's Common Equity over 5 years: stood at $341.4 million in 2022, then retreated by 7.85% to $314.6 million in 2023, then dropped by 8.57% to $287.6 million in 2024, then retreated by 7.16% to $267.0 million in 2025, then declined by 1.64% to $262.6 million in 2026.
- Per Business Quant, the three latest OABI Common Equity figures stand at $262.6 million (Q1 2026), $267.0 million (Q4 2025), and $277.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 262.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 262.65 Mn |
| Dec 31, 2025 | 267.03 Mn |
| Sep 30, 2025 | 277.44 Mn |
| Jun 30, 2025 | 262.06 Mn |
| Mar 31, 2025 | 273.52 Mn |
| Dec 31, 2024 | 287.62 Mn |
| Sep 30, 2024 | 291.73 Mn |
| Jun 30, 2024 | 294.18 Mn |
| Mar 31, 2024 | 301.39 Mn |
| Dec 31, 2023 | 314.59 Mn |
| Sep 30, 2023 | 324.55 Mn |
| Jun 30, 2023 | 333.81 Mn |
| Mar 31, 2023 | 340.80 Mn |
| Dec 31, 2022 | 341.37 Mn |
| Sep 30, 2022 | 232.71 Mn |
| Jun 30, 2022 | 226.94 Mn |
| Mar 31, 2022 | 224.92 Mn |
| Dec 31, 2021 | 234.31 Mn |
| Sep 30, 2021 | -6.90 Mn |
| Jun 30, 2021 | 15,029.00 |
| Mar 31, 2021 | 17,214.00 |